Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jvsv.2023.06.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Characteristics and Management of Rare Metabolic Bone Diseases: An Audit of the Rare Metabolic Bone Disease Registry of India.
Calcif Tissue Int
September 2025
Department of Endocrinology, Post-Graduate Institute of Medical Education and Research (PGIMER), 001, Nehru Extension Block, Chandigarh, India.
Rare diseases, defined by the 2002 Rare Disease Act, affect fewer than 5 in 10,000 individuals. Rare metabolic bone diseases (MBDs), such as osteogenesis imperfecta, hypophosphatasia, osteopetrosis, and other unclassified disorders, can disrupt bone development and remodeling, posing diagnostic and management challenges. This study analyzed data from the rarembd.
View Article and Find Full Text PDFPlasma transfusion practice: A five-year audit of plasma transfusion at 23 hospitals.
Transfusion
September 2025
Department of Pathology and Molecular Medicine, Kingston Health Sciences Centre and Queen's University, Kingston, Canada.
Background: There is limited high-quality evidence to guide plasma transfusion, and plasma transfusion practices remain variable.
Study Design And Methods: This is a retrospective cohort study that included adult medical and intensive care unit (ICU) inpatients (age ≥ 18 years) admitted to 23 hospitals in Canada between January 1, 2017, and December 31, 2022, when both whole blood derived (~290 mL) and apheresis plasma (~250 mL) were available for transfusion. Nine additional hospital sites with missing plasma data or coagulation testing were excluded.
Remote and digital services in UK general practice 2021-2023: the Remote by Default 2 longitudinal qualitative study synopsis.
Health Soc Care Deliv Res
September 2025
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Background: Remote services (in which the patient and staff member are not physically colocated) and digital services (in which a patient encounter is digitally mediated in some way) were introduced extensively when the COVID-19 pandemic began in 2020. We undertook a longitudinal qualitative study of the introduction, embedding, evolution and abandonment of remote and digital innovations in United Kingdom general practice. This synoptic paper summarises study design, methods, key findings, outputs and impacts to date.
View Article and Find Full Text PDFRegional Genetic Study: Monosymptomatic Nocturnal Enuresis and Array Technology.
Urol J
September 2025
Department of Child and Adolescent Psychiatry, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, TURKIYE.
Purpose: This study aimed to investigate the genetic heterogeneity of primary monosymptomatic nocturnal enuresis (PMNE) and assess potential genetic variants contributing to its etiology.
Materials And Methods: A total of 92 children aged 5-15 years with a positive family history of PMNE were evaluated. All patients underwent detailed urological and nephrological assessments to exclude organic causes.
Comparison between anterolateral standard and percutaneous antero-acromial approach in humeral intramedullary nailing (IMN). A radiological, functional, and ultrasound rotator cuff evaluation prospective study.
Musculoskelet Surg
September 2025
Orthopaedic and Traumatology Department, ASST Sette Laghi-Circolo Hospital and Macchi Foundation in Varese University Center, Viale Luigi Borri, 57, 21100, Varese, Italy.
Purpose: The aim of this study was to evaluate the radiological-functional outcomes and rotator cuff (RC) status following humeral intramedullary nailing (IMN), comparing the anterolateral standard approach (group 1) and the percutaneous antero-acromial approach (group 2).
Methods: This observational prospective monocentric study was conducted from August 2021 to March 2023. Inclusion criteria included: two-parts proximal (surgical neck) and diaphyseal Humeral fractures treated with IMN; 12-month follow-up; age between 18 and 85 years; good performance status (excluding neurologic deficits or mental disorders).